Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting

Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPi) are metabolized either via carboxylesterase (niraparib) or cytochrome P450 (CYP) enzymes (olaparib and rucaparib). Patients with advanced epithelial ovarian cancer (aOC) who receive concomitant medication metabolized by the CYP s...

Full description

Saved in:
Bibliographic Details
Main Authors: Bobbie J. Rimel (Author), Dana M. Chase (Author), Jessica Perhanidis (Author), Armen A. Ghazarian (Author), Ella Xiaoyan Du (Author), Travis Wang (Author), Jinlin Song (Author), Amanda K. Golembesky (Author), Jean A. Hurteau (Author), Linda Kalilani (Author), Ritu Salani (Author), Bradley J. Monk (Author)
Format: Book
Published: Elsevier, 2024-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available